Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782097 | 0.90 | NPC1 (0.45) | TDP1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4982116 | 0.77 | MEN1 (0.56) | MAPTMEN1KMT2A | |
| SCHEMBL14273458 | 0.75 | MEN1 (0.48) | TDP1MEN1KMT2A | |
| SCHEMBL4582366 | 0.75 | POLB (0.56) | TDP1MAPTMEN1KMT2A | |
| SCHEMBL4984595 | 0.73 | NPC1 (0.47) | TDP1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL633996 | 0.72 | CYP1A1 (0.64) | TDP1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL633997 | 0.72 | CYP1A1 (0.64) | TDP1MAPTNPC1RAB9AMEN1 | |
| SCHEMBL11119137 | 0.72 | MAPT (0.63) | TDP1MAPT | |
| SCHEMBL27713896 | 0.70 | MAPT (0.76) | TDP1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4797029 | 0.70 | MAPT (0.47) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | claimed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | claimed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | claimed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | TUBB1, TUBA1C, TUBB3 | TDP1 514/4885MAPT 85/4885NPC1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.